UFP Technologies is expected to report Q3 2026 revenue of $147.5 million and EPS of $2.63, with the stock currently trading at $314.85 against an average analyst target of $362.00.
Investors are primarily focused on gross margin expansion as the company continues to integrate several high-profile MedTech acquisitions made over the last 24 months.
Recent performance has been bolstered by double-digit organic growth and improved operational efficiencies from newly acquired manufacturing facilities. The market is looking for evidence that the company is successfully scaling its MedTech platform toward its long-term profitability targets.